NVEC:NASDAQNVE Corporation Analysis
Data as of 2026-05-20 - not real-time
$83.49
Latest Price
8/10Risk
Risk Level: High
Executive Summary
NVE Corporation is trading at $83.49, comfortably above its 20‑day SMA of $85.86 and well above the 50‑day SMA of $77.43, indicating a short‑term bullish bias. However, the MACD histogram is negative (-1.16) and the signal line is bearish, while the RSI sits at a neutral 49, suggesting limited upside momentum. Volatility is elevated at 54% over the past 30 days and beta exceeds 1.5, pointing to a stock that can swing sharply on market moves. Fundamentally, the company appears significantly overvalued – the DCF‑derived fair value is only $28.50 versus the current price, and the PE of 26.6 is well below the industry average of 38.7, yet the price‑to‑book of 6.93 and price‑to‑sales of 15.34 remain high. The dividend yield of 4.88% looks attractive, but a payout ratio of 127% raises concerns about sustainability. Recent earnings showed a 27% jump in net income and management highlighted a shift toward defense sales in FY2027, providing a potential growth catalyst.
Overall, the stock’s technical setup is modestly bullish, but the valuation gap and dividend sustainability issues suggest caution, especially for investors seeking value or reliable income.
Overall, the stock’s technical setup is modestly bullish, but the valuation gap and dividend sustainability issues suggest caution, especially for investors seeking value or reliable income.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish price above short‑term moving averages
- Negative MACD histogram indicating weakening momentum
- Elevated short‑term volatility
Medium Term
1–3 yearsCautious
Model confidence: 7/10
Key Factors
- Significant overvaluation relative to DCF fair value
- Unsustainable dividend payout ratio
- High beta and sector risk in semiconductors
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Potential upside from defense sales expansion
- Strong operating margins and cash generation
- Continued valuation pressure limiting upside
Key Metrics & Analysis
Financial Health
Revenue Growth5.30%
Profit Margin57.72%
P/E Ratio26.6
ROE25.22%
ROA15.96%
Debt/Equity1.55
P/B Ratio6.9
Op. Cash Flow$16.7M
Free Cash Flow$7.3M
Industry P/E38.7
Technical Analysis
TrendBullish
RSI49.2
Support$75.00
Resistance$110.03
MA 20$85.86
MA 50$77.43
MA 200$69.25
MACDBearish
VolumeIncreasing
Fear & Greed Index90.02
Valuation
Fair Value$28.50
GradeOvervalued
TypeGrowth
Dividend Yield4.88%
Risk Assessment
Beta1.59
Volatility54.73%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.